Leslie M Shaw

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
    L M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Clin Chem 44:381-7. 1998
  2. pmc Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
  3. ncbi request reprint Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 26:347-51. 2004
  4. ncbi request reprint Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, School of Pharmacy, University of Pittsburgh, PA 15261, USA
    Am J Transplant 3:534-42. 2003
  5. pmc PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neurosignals 16:19-23. 2008
  6. ncbi request reprint Monitoring of mycophenolic acid in clinical transplantation
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Ther Drug Monit 24:68-73. 2002
  7. ncbi request reprint Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Drug Discov 6:295-303. 2007
  8. ncbi request reprint Therapeutic drug monitoring of mycophenolic acid
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Clin J Am Soc Nephrol 2:1062-72. 2007
  9. ncbi request reprint Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
    L M Shaw
    Departments of Pathology and Laboratory Medicine and Surgery, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Clin Biochem 34:17-22. 2001
  10. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012

Detail Information

Publications71

  1. ncbi request reprint Prospective investigations of concentration-clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring
    L M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Clin Chem 44:381-7. 1998
    ....
  2. pmc Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Ann Neurol 65:403-13. 2009
    ..Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects...
  3. ncbi request reprint Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 26:347-51. 2004
    ....
  4. ncbi request reprint Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, School of Pharmacy, University of Pittsburgh, PA 15261, USA
    Am J Transplant 3:534-42. 2003
  5. pmc PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Neurosignals 16:19-23. 2008
    ..This validation data will hopefully provide biomarker test performance needed for effective measurement of the efficacy of new treatment and prevention therapeutic agents...
  6. ncbi request reprint Monitoring of mycophenolic acid in clinical transplantation
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Ther Drug Monit 24:68-73. 2002
  7. ncbi request reprint Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Drug Discov 6:295-303. 2007
    ....
  8. ncbi request reprint Therapeutic drug monitoring of mycophenolic acid
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Clin J Am Soc Nephrol 2:1062-72. 2007
  9. ncbi request reprint Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
    L M Shaw
    Departments of Pathology and Laboratory Medicine and Surgery, University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Clin Biochem 34:17-22. 2001
    ..Further investigations are needed to evaluate the pharmacologic activity of the newly described acyl glucuronide metabolite of mycophenolic acid which has been shown to inhibit, in vitro, inosine monophosphate dehydrogenase...
  10. pmc Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
    Neurology 79:897-905. 2012
    ..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
  11. pmc Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
    John Q Trojanowski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 6:230-8. 2010
    ..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies...
  12. pmc CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, CNDR, University of Pennsylvania School of Medicine, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Acta Neuropathol 124:23-35. 2012
    ....
  13. pmc Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    PLoS ONE 8:e55531. 2013
    ....
  14. pmc Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms
    David J Irwin
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
    Arch Neurol 69:1018-25. 2012
    ..To use values of cerebrospinal fluid tau and β-amyloid obtained from 2 different analytical immunoassays to differentiate Alzheimer disease (AD) from frontotemporal lobar degeneration (FTLD)...
  15. pmc Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
    Leslie M Shaw
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Acta Neuropathol 121:597-609. 2011
    ....
  16. pmc Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
    Alice S Chen-Plotkin
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Ann Neurol 69:655-63. 2011
    ..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
  17. pmc Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology
    Selam Negash
    Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
    Alzheimers Dement 9:e89-95. 2013
    ..The aim of the present study was to examine cognitive and cerebral reserve factors associated with resilient functioning in the setting of AD pathology...
  18. pmc Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients
    Michal J Figurski
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, USA
    Alzheimers Dement 8:250-60. 2012
    ..The goal of this investigation was to address these problems by improving the performance of the bioanalytical method...
  19. ncbi request reprint Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters
    Michał J Figurski
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Transplant 17:68-78. 2012
    ..Additional MPA AUC measurements are recommended when trough levels do not explain the clinical picture.<br />..
  20. pmc Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
    William T Hu
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Acta Neuropathol 120:385-99. 2010
    ....
  21. doi request reprint Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers
    Ju Hee Kang
    Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Clin Chem 59:903-16. 2013
    ....
  22. pmc Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease
    Li San Wang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Alzheimers Dis 31:439-45. 2012
    ....
  23. pmc Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Alzheimers Dement 8:483-9. 2012
    ..Therefore, we examined the relationship between CVRF and amyloid-β (Aβ) brain burden measured by Pittsburgh Compound B-positron emission tomography (PiB-PET) studies in the Alzheimer's Disease Neuroimaging Initiative...
  24. pmc Can MRI screen for CSF biomarkers in neurodegenerative disease?
    Corey T McMillan
    Department of Neurology, University of Pennsylvania, Philadelphia, USA
    Neurology 80:132-8. 2013
    ..In this study, we evaluate the utility of MRI as a noninvasive screening procedure for the differential diagnosis of AD and FTLD...
  25. doi request reprint CSF Apo-E levels associate with cognitive decline and MRI changes
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP, Maloney 3rd, 36th and Spruce Streets, Philadelphia, PA, 19104 4283, USA
    Acta Neuropathol 127:621-32. 2014
    ....
  26. doi request reprint Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine
    Michal J Figurski
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 30:445-55. 2008
    ..86, 4.1, and 83%, respectively. The model with 2 hours as the last time point is also recommended for the SRL group for practical reasons, with the above parameters of 0.77, 11.3, and 69%, respectively...
  27. pmc Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis
    David J Irwin
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Alzheimer s Disease Core Center, Institute on Aging, Philadelphia, Pennsylvania, USA
    J Neurol Neurosurg Psychiatry 84:163-9. 2013
    ..To clarify this issue, we compared a large C9P cohort with carefully matched non-expansion (C9N) cases with a known or highly-suspected underlying TAR DNA-binding protein 43 (TDP-43) proteinopathy...
  28. pmc Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification
    Christos Davatzikos
    Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neurobiol Aging 32:2322.e19-27. 2011
    ..In summary, both SPARE-AD and CSF biomarkers showed high baseline sensitivity, however, many MCI-NC had abnormal baseline SPARE-AD and CSF biomarkers. Longer follow-up will elucidate the specificity of baseline measurements...
  29. pmc Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, HUP, Maloney 3rd JQT or 7th LMS Floor, 36th and Spruce Streets, Philadelphia, PA, 19104 4283, USA
    Acta Neuropathol 122:401-13. 2011
    ..Our study emphasizes the need for a better understanding of the biology and dynamics of plasma Aβ as well as the need for longer term studies to determine the clinical utility of measuring plasma Aβ...
  30. pmc Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
    Sunil Patel
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Fluids Barriers CNS 9:7. 2012
    ..abstract:..
  31. ncbi request reprint Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients
    Sandra G Solari
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 27:417-21. 2005
    ..A prospective concentration-control de novo study design is recommended as the most appropriate way to fully evaluate the potential utility of C2 monitoring in heart transplant patients...
  32. doi request reprint Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease
    Ju Hee Kang
    Department of Pathology and Laboratory Medicine, Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
    Methods 56:484-93. 2012
    ....
  33. ncbi request reprint Sensitive, high throughput HPLC-MS/MS method with on-line sample clean-up for everolimus measurement
    Magdalena Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Ther Drug Monit 28:484-90. 2006
    ....
  34. pmc Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
    Roy Hamilton
    Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
    Ann Neurol 68:535-40. 2010
    ....
  35. ncbi request reprint Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report
    Ashok Kumar B Jain
    Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA
    Liver Transpl 8:838-40. 2002
    ..Increase in trough concentration, peak concentration area under the curve concentration, and prolongation of half-life of sirolimus has been shown in a patient who was on a low dose (one fifth the recommended dose) of nelfinavir...
  36. doi request reprint High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites
    Michal J Figurski
    Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Ther Drug Monit 31:717-26. 2009
    ..02%. This method was successfully applied to analyze over 11,000 samples for total analytes, and over 8000 samples for free analytes in plasma, and has been in operation for nearly 3 years without loss of performance...
  37. pmc Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment
    William T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4283, USA
    Acta Neuropathol 119:669-78. 2010
    ..In summary, our targeted proteomic screen revealed novel CSF biomarkers that can improve the distinction between AD and non-AD cases by established biomarkers alone...
  38. doi request reprint Evaluation of performance of new, isotopically labeled internal standard ([13c2d4]RAD001) for everolimus using a novel high-performance liquid chromatography tandem mass spectrometry method
    Magdalena A Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Ther Drug Monit 33:460-3. 2011
    ....
  39. ncbi request reprint Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients
    Marika Schubert
    Thomas E Starzl Transplantation Institute of the Children s Hospital of Pittsburgh, Pittsburgh, PA, USA
    Am J Transplant 4:767-73. 2004
    ..During conversion of subjects from TAC to combined TAC and SRL, aggressive therapeutic drug monitoring must be used to individualize therapy and avoid serous adverse events...
  40. ncbi request reprint Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus
    Tomasz Pawinski
    Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 7 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Clin Chem 48:1497-504. 2002
    ..We developed a practical method for estimation of MPA AUCs. Regression equations were developed using repeated cross-validation for randomly chosen subsets, characterized statistically, and verified for acceptable performance...
  41. pmc Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup
    Magdalena Korecka
    Department Pathology and Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:2209-16. 2010
    ..1g of tissue for 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha)-VI, respectively, for the brain tissue method. No ion suppression or enhancement of the detection of 8-isoPGF(2alpha), 8,12-isoPF(2alpha)-VI or both internal standards was found...
  42. pmc Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease
    Mark Yarchoan
    Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, United States
    J Neurol Sci 333:9-12. 2013
    ..Our results support previous reports of reduced levels of plasma CRP in AD and indicate its potential utility as a biomarker for the diagnosis of AD. ..
  43. pmc Human Alzheimer and inflammation biomarkers after anesthesia and surgery
    Junxia X Tang
    Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Anesthesiology 115:727-32. 2011
    ..The authors studied human cerebrospinal fluid (CSF) biomarkers during surgery...
  44. ncbi request reprint Review of the newest HPLC methods with mass spectrometry detection for determination of immunosuppressive drugs in clinical practice
    Magdalena Korecka
    University of Pennsylvania, Department Pathology and Laboratory Medicine, Philadelphia, PA, USA
    Ann Transplant 14:61-72. 2009
    ..In conclusion, important features of LC-MS methodology for immunosuppressive drugs include: shortened analysis time, increased throughput, selectivity and lower cost of analysis.<br /> <br />..
  45. pmc CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease
    A Siderowf
    Department of Neurology, 330 South 9th Street, Second Floor, Philadelphia, PA 19107, USA
    Neurology 75:1055-61. 2010
    ..Cognitive decline associated with Parkinson disease (PD) is common and highly disabling. Biomarkers that help identify patients at risk for cognitive decline would be useful additions to the clinical management of the disease...
  46. pmc Novel CSF biomarkers for frontotemporal lobar degenerations
    W T Hu
    Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104 4283, USA
    Neurology 75:2079-86. 2010
    ..To identify antemortem CSF diagnostic biomarkers that can potentially distinguish between the 2 main causes of frontotemporal lobar degeneration (FTLD), i.e., FTLD with TDP-43 pathology (FTLD-TDP) and FTLD with tau pathology (FTLD-tau)...
  47. ncbi request reprint Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients
    R Venkataramanan
    Department of Pharmaceutical Sciences, Pathology, and Surgery, University of Pittsburgh, Pennsylvania 15261, USA
    J Clin Pharmacol 41:542-51. 2001
    ....
  48. ncbi request reprint Violent injuries among women in an urban area
    J A Grisso
    Department of Biostatistics and Epidemiology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104 6021, USA
    N Engl J Med 341:1899-905. 1999
    ....
  49. pmc Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA
    Acta Neuropathol 126:659-70. 2013
    ....
  50. pmc Design of comprehensive Alzheimer's disease centers to address unmet national needs
    John Q Trojanowski
    Institute on Aging, Philadelphia, PA, USA
    Alzheimers Dement 6:150-5. 2010
    ..The intent of this position paper is to stimulate thinking and foster the development of other or alternative models for a systematic approach to the study of dementia and movement disorders...
  51. pmc CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease
    Jon B Toledo
    Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Acta Neuropathol 126:683-97. 2013
    ..Hence, we suggest that inclusion of measures of CSF α-syn and calculation of α-syn-p-tau181-Mis improves the diagnostic sensitivity/specificity of classic CSF AD biomarkers and better predicts longitudinal cognitive changes. ..
  52. doi request reprint Quantitation of tacrolimus in whole blood using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS)
    Keri J Donaldson
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 603:479-87. 2010
    ..75 mg/L. The concentration of drug is determined by comparing peak-area ratios for tacrolimus and internal standard to a standard curve constructed using non-weighted linear through zero regression...
  53. doi request reprint Quantitation of sirolimus using liquid chromatography-tandem mass spectrometry (LC-MS-MS)
    Magdalena Korecka
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 603:469-77. 2010
    ..5 microg/L. The quantification of drug is made from standard curve using peak-area ratio of analyte vs. internal standard. Calibration curve is constructed using non-weighted linear through zero regression...
  54. ncbi request reprint Accidental intravenous colchicine poisoning
    Jonathan S Sussman
    Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Ther Drug Monit 26:688-92. 2004
    ..These patients thus received a bolus dose of 20 mg of intravenous colchicine rather than the intended 2-mg dose. An intravenous dose of this magnitude has not previously been reported...
  55. pmc IOP1, a novel hydrogenase-like protein that modulates hypoxia-inducible factor-1alpha activity
    Jianhe Huang
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Biochem J 401:341-52. 2007
    ..The results collectively provide evidence that IOP1 is a component of the protein network that regulates HIF-1alpha in mammalian cells...
  56. ncbi request reprint Evaluation of tricyclic antidepressant false positivity in a pediatric case of cyproheptadine (periactin) overdose
    Constance M Yuan
    Department of Pathology and Laboratory Medicine, The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Ther Drug Monit 25:299-304. 2003
    ..These findings showed that the cross-reactivity correlated with the presence of the cyproheptadine metabolite, highlighting the value of confirmatory toxicologic testing of routine rapid toxicologic screens...
  57. ncbi request reprint Substance use measures among women in early pregnancy
    N Markovic
    Women s Health Program, Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Am J Obstet Gynecol 183:627-32. 2000
    ..Our purpose was to compare self-reported and biochemical measures for tobacco, marijuana, and cocaine exposures among women early in pregnancy...
  58. ncbi request reprint New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion
    H S Bonner
    Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia 19104, USA
    J Clin Pharmacol 42:166-74. 2002
    ..v. delivery. These data suggest that the protein-bound form of WR-1065 plays an important role in contributing to the bioavailability of this clinically useful cytoprotective drug...
  59. ncbi request reprint Anticholinergic toxicity associated with lupine seeds as a home remedy for diabetes mellitus
    S Tsiodras
    Department of Internal Medicine, Albert Einstein Medical Center, University of Pennsylvania, Philadelphia, PA, USA
    Ann Emerg Med 33:715-7. 1999
    ..This case highlights the need for emergency care providers to be aware of the health hazards that can be associated with the use of such home remedies...
  60. ncbi request reprint Therapeutic monitoring of mycophenolic acid in liver transplant patients
    Raman Venkataramanan
    Liver Transpl 10:503-5. 2004
  61. doi request reprint Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness
    Laurence Chan
    Health Sciences Center, University of Colorado, Denver, CO 80262, USA
    Transplantation 85:821-6. 2008
    ..Clinical data are lacking concerning concomitant administration of everolimus and tacrolimus in renal transplant recipients...
  62. ncbi request reprint The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
    Teun van Gelder
    Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands
    Transplantation 80:S244-53. 2005
    ....
  63. ncbi request reprint International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring
    David W Holt
    Analytical Unit, St George s Hospital Medical School, London, UK
    Ther Drug Monit 24:59-67. 2002
    ..This paper sets out the goals of the working group in light of the developments that have occurred in the field of immunosuppressive drug monitoring since the publication of the last consensus documents...
  64. ncbi request reprint Therapeutic drug monitoring of mycophenolate mofetil in transplantation
    Teun van Gelder
    Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus Medical Center, Rotterdam, The Netherlands
    Ther Drug Monit 28:145-54. 2006
    ..The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies...
  65. ncbi request reprint Analytic aspects of cyclosporine monitoring, on behalf of the IFCC/IATDMCT Joint Working Group
    Raymond G Morris
    Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, South Australia 5011, Australia
    Ther Drug Monit 26:227-30. 2004
    ..This includes the CsA method selection criteria adopted by a large percentage of laboratories in various surveys, indicating that the least specific mFPIA methods have been widely adopted...
  66. ncbi request reprint Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy
    Jill S Warrington
    Duke University Medical Center, Department of Pathology, Box 3712, Durham, NC 27710, USA
    Expert Opin Drug Metab Toxicol 1:487-503. 2005
    ..The potential role of drug-metabolising enzymes in contributing to these drug-drug interactions is briefly considered...
  67. ncbi request reprint The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA
    David M Margolis
    Department of Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, USA
    J Acquir Immune Defic Syndr 31:45-9. 2002
    ..The possibility that MMF may enhance the effect of selected NRTIs and be tolerated in late stage HIV disease deserves careful randomized study...
  68. ncbi request reprint Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11
    Aimee M Powelka
    Brigham and Women s Hospital, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Traffic 5:20-36. 2004
    ..Consistent with these observations being relevant for cell motility, mutant forms of ARF6 that affect either actin rearrangement or recycling inhibit the motility of a breast cancer cell line...
  69. ncbi request reprint Stability of mycophenolic acid in plasma samples from patients during mycophenolate mofetil therapy
    Tomasz Pawinski
    Department of Drug Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Poland
    Acta Pol Pharm 60:121-4. 2003
    ..Monitoring human plasma samples stored at -20 degrees C showed that MPA was stable at this temperature for at least 3 weeks. MPA concentrations were found to be stable also up to 96 hours when stored at 4 degrees C...
  70. ncbi request reprint Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation
    Julie M Bullock
    Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Ther Drug Monit 28:62-6. 2006
    ..All limited sampling models tested were unbiased in their results, and a 4-sample scheme proved to adequately characterize busulfan pharmacokinetics, and should allow for a reduced sampling frequency for therapeutic drug monitoring...
  71. ncbi request reprint Evaluation of a no-pretreatment cyclosporin A assay on the Dade Behring dimension RxL clinical chemistry analyzer
    Andrea R Terrell
    Division of Laboratory Medicine, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110 1093, USA
    Clin Chem 48:1059-65. 2002
    ..In a multicenter study we evaluated a new, direct (no pretreatment) CsA assay on the Dade Behring Dimension RxL system and compared results with those from the Abbott TDx CsA immunoassay and a HPLC method...